Mar Rhino

Xylometazoline Hydrochloride, the active ingredient in Mar Rhino, is an imidazoline nasal decongestant presented as a nasal spray for nasal use. It relieves nasal congestion associated with the common cold, sinusitis, and allergic rhinitis in both adults and children. GNH USA supplies Mar Rhino as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is an imidazoline nasal decongestant that reduces swelling of the nasal mucosa.

- Common cold nasal congestion: provides rapid relief of a blocked nose. - Sinusitis‑related congestion: decreases mucosal edema to improve sinus drainage. - Allergic rhinitis: alleviates nasal blockage caused by allergic inflammation.

Adverse reactions may occur with nasal spray use.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing. - Mild headache. - Altered taste or bitter taste. - Transient epistaxis (minor nosebleed).

Serious or Rare Side Effects: - Severe or prolonged nosebleeds. - Hypertension or marked increase in blood pressure. - Tachycardia or arrhythmia. - Allergic reactions including rash, swelling, or anaphylaxis. - Rebound congestion (rhinitis medicamentosa) after prolonged use. - Vision changes or ocular pressure increase (rare).

Use Mar Rhino according to professional guidance and observe safety measures.

- Age limitation: not recommended for children under 6 years unless directed by a physician. - Duration of use: limit to 3‑5 days to avoid rebound congestion. - Pregnancy and lactation: consult a healthcare professional before use. - Cardiovascular disease: use with caution due to possible systemic vasoconstriction. - Nasal surgery or trauma: avoid until the nasal passages have healed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Consider potential drug interactions when using Mar Rhino.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may cause severe hypertension. - Other topical nasal decongestants: additive vasoconstriction can increase systemic effects.

Moderate Interactions (Monitor Closely): - Oral antihypertensive agents: may reduce blood‑pressure control. - Tricyclic antidepressants: possible enhanced cardiovascular stimulation. - Beta‑blockers: monitor for bradycardia or blood‑pressure changes.